Evol’s Mission

To discover and therapeutically exploit mechanisms of cancer cell resistance, and to develop new targeted therapies using our proteo-genomic system, metadata analysis and predictive analytics. Our goal is to maximize medical impact, extending and improving lives - making the deadliest cancers survivable.


Newly Published Research:

AACR Journals - Molecular Cancer Therapeutics

"Identification of the serine biosynthesis pathway as a critical component of BRAF inhibitor resistance of melanoma, pancreatic, and non-small cell lung cancer cells"

Kayleigh C Ross, Andrew J. Andrews, Christopher D Marion, Timothy J. Yen and Vikram Bhattacharjee*
Published OnlineFirst May 12, 2017. DOI: 10.1158/1535-7163.MCT-16-0798

* - Corresponding Author